Assenagon Asset Management S.A. Lowers Holdings in uniQure N.V. $QURE

Assenagon Asset Management S.A. trimmed its stake in uniQure N.V. (NASDAQ:QURE) by 75.8% during the 1st quarter, HoldingsChannel reports. The fund owned 146,749 shares of the biotechnology company’s stock after selling 460,174 shares during the quarter. Assenagon Asset Management S.A.’s holdings in uniQure were worth $2,399,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of QURE. CIBC Private Wealth Group LLC bought a new position in uniQure in the 3rd quarter valued at approximately $50,000. Torren Management LLC purchased a new stake in shares of uniQure during the fourth quarter valued at $28,000. FNY Investment Advisers LLC boosted its position in shares of uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 718 shares during the last quarter. IFP Advisors Inc bought a new stake in uniQure in the 4th quarter worth about $48,000. Finally, Knott David M Jr bought a new stake in uniQure in the 3rd quarter worth about $117,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Stock Down 2.8%

QURE stock opened at $46.06 on Wednesday. The business’s 50-day moving average price is $29.02 and its 200-day moving average price is $23.40. The stock has a market cap of $2.91 billion, a P/E ratio of -13.24 and a beta of 0.98. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. On average, equities research analysts forecast that uniQure N.V. will post -3.65 EPS for the current year.

Insider Buying and Selling

In other uniQure news, insider Walid Abi-Saab sold 45,000 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the sale, the insider directly owned 169,669 shares of the company’s stock, valued at $4,251,905.14. This trade represents a 20.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Gut sold 7,552 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $26.05, for a total value of $196,729.60. Following the completion of the transaction, the director directly owned 27,435 shares in the company, valued at approximately $714,681.75. This represents a 21.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 360,980 shares of company stock worth $14,617,140 in the last three months. Corporate insiders own 4.65% of the company’s stock.

Analyst Ratings Changes

QURE has been the topic of several research analyst reports. Leerink Partners upped their target price on shares of uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. TD Cowen reiterated a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Stifel Nicolaus set a $28.00 price target on uniQure in a report on Tuesday, May 5th. HC Wainwright raised their price target on uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Twelve analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and a consensus price target of $64.17.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.